Galectin Therapeutics Inc.
GALT · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $272 | $134 | $77 | $81 |
| - Cash | $12 | $14 | $7 | $15 |
| + Debt | $122 | $121 | $108 | $106 |
| Enterprise Value | $383 | $241 | $178 | $172 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | -$0 | -$0 | -$0 |
| % Margin | – | – | – | – |
| EBITDA | -$6 | -$6 | -$8 | -$10 |
| % Margin | – | – | – | – |
| Net Income | -$8 | -$8 | -$10 | -$12 |
| % Margin | – | – | – | – |
| EPS Diluted | -0.13 | -0.12 | -0.15 | -0.19 |
| % Growth | -8.3% | 20% | 21.1% | – |
| Operating Cash Flow | -$4 | -$7 | -$8 | -$13 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$4 | -$7 | -$8 | -$13 |